• 46,000 estimated new cases per year
  • Approximately 8,100 deaths per year from the disease
  • Endometrioid adenocarcinoma arises in the endometrium and accounts for approximately 90% of cases
  • Median age is 63 years
  • Most common presenting symptom is irregular vaginal bleeding
  • Risk factors include unopposed oestrogen therapy, obesity, chronic anovulation, tamoxifen use, diabetes, and nulliparity
  • Staging is surgical according to International Federation of Gynaecology and Obstetrics (FIGO) guidelines
  • Uterine sarcomas and carcinomas are staged differently
  • Primary surgery with hysterectomy, bilateral salpingo-oophorectomy and lymphadenectomy is curative in majority of cases
  • Radiation alone may be used for inoperable patients and/or palliation
  • Risk factors for recurrence or extrauterine spread include deep myometrial invasion, moderate- to high-grade histology, and lymphovascular space invasion (LVSI)
  • Adjuvant radiation may be used in patients with high-intermediate and high-risk disease
  • Adjuvant chemotherapy with or without radiation therapy may be administered in cases with aggressive histology, such as serous, clear cell, carcinosarcoma, or leiomyosarcoma and undifferentiated endometrial sarcoma
  • Chemotherapy, radiation, or combination therapy is used in locally advanced, metastatic, or recurrent endometrial cancer
  • Cytoreductive surgery is associated with improved overall survival
  • Salvage radiotherapy is utilized for recurrences after surgery alone
  • Endocrine therapy with progestins and/or tamoxifen may be used when avoidance of cytotoxic chemotherapy is desired
  • Tumour-directed radiation therapy may be employed in cases of locally advanced, metastatic, or recurrent disease
  • Survival is strongly correlated with surgical stage, tumour grade, and histology
  • Uterine clear cell and serous carcinomas are associated with a worse prognosis than endometrioid adenocarcinomas

TestimonialsWhat They Are Saying

(Visited 1 times, 1 visits today)
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

Leave a Reply

Your email address will not be published. Required fields are marked *